TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02525367

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online cognitive training
Description: The intervention is a computerized, online training programme which aims to train several cognitive abilities; especially the executive functions, attention, working memory and processing speed. The mental processes that are appealed to by the intervention are similar to processes that are trained in classic face-to-face training methods. Both the intervention protocol and the active control condition will contain several games that have the participant train cognitive functions/perform cognitive activities for 8 weeks, 3 times a week, 45-60 minutes each session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online cognitive training
Description: The intervention is a computerized, online training programme which aims to train several cognitive abilities; especially the executive functions, attention, working memory and processing speed. The mental processes that are appealed to by the intervention are similar to processes that are trained in classic face-to-face training methods. Both the intervention protocol and the active control condition will contain several games that have the participant train cognitive functions/perform cognitive activities for 8 weeks, 3 times a week, 45-60 minutes each session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online cognitive training
Description: The intervention is a computerized, online training programme which aims to train several cognitive abilities; especially the executive functions, attention, working memory and processing speed. The mental processes that are appealed to by the intervention are similar to processes that are trained in classic face-to-face training methods. Both the intervention protocol and the active control condition will contain several games that have the participant train cognitive functions/perform cognitive activities for 8 weeks, 3 times a week, 45-60 minutes each session.
Study: NCT01989156

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: THS 2.2 Menthol (mTHS 2.2)
Description: THS 2.2 Menthol ad libitum for 5 days in confinement prolonged by 86 days in an ambulatory setting

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Menthol Conventional Cigarette (mCC)
Description: Subject's own preferred brand of mCC ad libitum for 5 days in confinement prolonged by 86 days in an ambulatory setting

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Smoking Abstinence (SA)
Description: SA for 5 days in confinement prolonged by 86 days in an ambulatory setting
Study: NCT02746783

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Single dose MUTAGRIP® influenza vaccine
Description: All subjects will receive either a single or double doses of MUTAGRIP® containing A/California/7/2009 (H1N1); A/Texas/50/2012 (H3N2); B/Massachusetts/2/2012. The double dose regimen will be administered at the same time.
Study: NCT02746783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Double dose of MUTAGRIP® influenza vaccine
Description: All subjects will receive either a single or double doses of MUTAGRIP® containing A/California/7/2009 (H1N1); A/Texas/50/2012 (H3N2); B/Massachusetts/2/2012. The double dose regimen will be administered at the same time.
Study: NCT03164876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AUT00206
Description: 4 capsules of 200mg AUT00206, twice daily, to take orally with food for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 capsules of placebo, twice daily, to take orally with food for 4 weeks
Study: NCT02537561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Study: NCT04675216

Intervention type: PROCEDURE
Intervention: Posterior fossa intracranial pressure measurement
Description: Measurement of posterior fossa pressure in an invasive way

Intervention type: PROCEDURE
Intervention: Posterior fossa intracranial pressure measurement
Description: Measurement of posterior fossa pressure in an invasive way
Study: NCT00218517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selegiline hydrochloride
Description: Daily oral selegiline, 5 mg po qd x 7 days, then 5 mg po bid for 7 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules using blue 00 capsules
Study: NCT02525367

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active control condition
Description: The active control condition consists of cognitive activities that do not intend to train cognitive functions based on 'cristallized intelligence', such as trivia. Both the intervention protocol and the active control condition will contain several games that have the participant train cognitive functions/perform cognitive activities for 8 weeks, 3 times a week, 45-60 minutes each session.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active control condition
Description: The active control condition consists of cognitive activities that do not intend to train cognitive functions based on 'cristallized intelligence', such as trivia. Both the intervention protocol and the active control condition will contain several games that have the participant train cognitive functions/perform cognitive activities for 8 weeks, 3 times a week, 45-60 minutes each session.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active control condition
Description: The active control condition consists of cognitive activities that do not intend to train cognitive functions based on 'cristallized intelligence', such as trivia. Both the intervention protocol and the active control condition will contain several games that have the participant train cognitive functions/perform cognitive activities for 8 weeks, 3 times a week, 45-60 minutes each session.
Study: NCT02002429

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intra-articular injection
Description: Intra-articular injection into the affected facet joint(s) with 0.5 ml of a 50:50 solution containing 10 mg of depo-methylprednisolone and 0.5% bupivacaine. If the subject has a positive block a radiofrequency denervation will be performed at the affected joint.
Study: NCT03585452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Infusion
Description: Patients with additional dexmedetomidine infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol based general anesthesia
Description: Patients with typical anaesthetic regimens
Study: NCT01742793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide (Revlimid) and romidepsin (Istodax)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide (Revlimid) and romidepsin (Istodax)
Study: NCT01076829

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spice polyphenols
Description: spice

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Spice polyphenols
Description: spice
Study: NCT00606723

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hematopoietic stem cells from bone marrow or peripheral blood
Description: \> = 2 x 10\*8 nucleated cells (WBC)/kg body weight of the recipient or rather \> = 4 x 10\*6 nucleated CD34+ cells / kg body weight are required for engraftment. Suspension of stem cells is administered via intravenous infusion.
Study: NCT02537561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Study: NCT03533387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MN-166
Description: an orally available small molecule drug approved in Japan and Korea for asthma and post-stroke complications and has been prescribed for these indications for more than 25 years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MN-166
Description: an orally available small molecule drug approved in Japan and Korea for asthma and post-stroke complications and has been prescribed for these indications for more than 25 years

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MN-166
Description: an orally available small molecule drug approved in Japan and Korea for asthma and post-stroke complications and has been prescribed for these indications for more than 25 years
Study: NCT02803918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lixisenatide (AVE0010)
Description: Pharmaceutical form: solution~Route of administration: subcutaneous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: solution~Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basal Insulin
Description: Pharmaceutical form: solution~Route of administration: subcutaneous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Basal Insulin
Description: Pharmaceutical form: solution~Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Pharmaceutical form: tablet~Route of administration: oral
Study: NCT02537561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Study: NCT02803918

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Pharmaceutical form: tablet~Route of administration: oral
Study: NCT01224639

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TDV - Low Dose
Description: TDV is a tetravalent dengue vaccine comprised of four recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4. Low dose contains: TDV-1: 8 x 10\^3 PFU, TDV-2: 5 x 10\^3 PFU, TDV-3: 1 x 10\^4 PFU, and TDV-4: 2 x 10\^5 PFU, total virus per dose 2.2 x 10\^5 PFU

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TDV - Low Dose
Description: TDV is a tetravalent dengue vaccine comprised of four recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4. Low dose contains: TDV-1: 8 x 10\^3 PFU, TDV-2: 5 x 10\^3 PFU, TDV-3: 1 x 10\^4 PFU, and TDV-4: 2 x 10\^5 PFU, total virus per dose 2.2 x 10\^5 PFU

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TDV - High Dose
Description: TDV is a tetravalent dengue vaccine comprised of four recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4. High dose contains TDV-1: 2 x 10\^4 PFU, TDV-2: 5 x 10\^4 PFU, TDV-3: 1 x 10\^5 PFU, and TDV-4: 3 x 10\^5 PFU, total virus per dose : 4.7 x 10\^5 PFU. TDV administered intradermally.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TDV - High Dose
Description: TDV is a tetravalent dengue vaccine comprised of four recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4. High dose contains TDV-1: 2 x 10\^4 PFU, TDV-2: 5 x 10\^4 PFU, TDV-3: 1 x 10\^5 PFU, and TDV-4: 3 x 10\^5 PFU, total virus per dose : 4.7 x 10\^5 PFU. TDV administered intradermally.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Phosphate Buffered Saline (PBS)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Phosphate Buffered Saline (PBS)
Study: NCT03181542

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Infrared illumination
Description: Infrared illumination of veins using the FDA approved AccuVein (AccuVein, Inc., Huntington, NY) device.
Study: NCT03467633

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-intensity interval training
Description: Participants in the HIIT group will receive 3-weeks of tri-weekly supervised exercise sessions at the UOHI prior to their scheduled electro-cardioversion. The session will last 23 minutes in duration and consist of a 2-minute warm-up at 50% of peak power output (PPO), 2 x 8-minute interval training blocks of 30 seconds at 80-100% of PPO interspersed with 30-seconds of active recovery and a 1-minute cool down at 25 % of PPO. The sessions will be lead by a Registered Kinesiologist.
Study: NCT00247728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PI-88
Description: Once-daily SC injection for four consecutive days per week, for 3 weeks out of every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PI-88
Description: Once-daily SC injection for four consecutive days per week, for 3 weeks out of every 4 weeks
Study: NCT03424031

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Verticalization
Description: To allow the verticalization of hemiplegic patients, we will use a device commonly used in rehabilitation: the standing (or standing) brand Thera Trainer . This device makes it possible to keep the patient standing despite the motor and postural deficits thanks to knee, buttocks and an anterior support for the upper limbs. Verticalization with this device requires the presence of one or two caregivers (including at least one re-educator), depending on the possibilities of participation of the patient.
Study: NCT01920815

Intervention type: OTHER
Intervention: No interventions

Intervention type: OTHER
Intervention: No interventions

Intervention type: OTHER
Intervention: No interventions
Study: NCT03366064

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pemetrexed and donor-derived NK cell infusion
Description: Patients are administered with donor-derived NK cells one week after pemetrexed infusion
Study: NCT01924169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 5 mg/day by mouth on Monday, Wednesday and Friday for 3 months. Process repeated for up to 2 years.~If IgG levels do not improve, frequency of lenalidomide increased to 5 mg/day by mouth for additional 3 months and if response is achieved, lenalidomide continued at 5mg/day 3 month on/3 month off for a total of 2 years.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Vaccine
Description: Administered as injection yearly, during the fall/winter season.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumovax Vaccine
Description: Administered by injection once between month 6 and month 21. Patients, who have received the Pneumovax vaccine within last 5 years, will not receive Pneumovax vaccination.
Study: NCT03821012

Intervention type: OTHER
Intervention: in-hospital process optimization

Intervention type: OTHER
Intervention: PPCI hospital-based regional STEMI transfer network construction

Intervention type: OTHER
Intervention: the whole-city STEMI care network construction
Study: NCT02002429

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Medial branch block
Description: Medial branch blocks at the nerves that supply the affected facet joint(s) with 0.5 ml of a 50:50 solution containing 10 mg of depo-methylprednisolone and 0.5% bupivacaine. If the subject has a positive block a radiofrequency denervation will be performed at the affected joint.
Study: NCT04007822

Intervention type: BEHAVIORAL
Intervention: Pain Navigator Tool
Description: The Pain Navigator Tool (PNT) was developed recently with the aim to empower patients through helping them to discuss their main concerns about pain, and to help therapists to prioritise addressing these concerns (Blomkvist et al., 2018). The initial pilot study with this tool improved the content of the consultations and patient engagement, and led to better patient-therapist interaction in a small population of healthcare providers and patients (Blomkvist et al., 2018). As it endeavours to facilitate the implementation of self-management in patients with chronic pain, the PNT aligns with the Scottish Intercollegiate Guidelines Network (SIGN) guideline for chronic pain and the Scottish Government's strategic vision (Scottish Government, 2011; SIGN, 2013).
Study: NCT00297089

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABT-751
Description: 200 mg ABT-751 daily for 14 days every 21 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pemetrexed
Description: Standard pemetrexed every 21 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: pemetrexed
Description: Standard pemetrexed every 21 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo daily for 14 days every 21 days
Study: NCT02558816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib + GA101 +GDC-0199
Description: Step A : 9 patients receive the combination of Ibrutinib + GA101 Step B : 24 patients receive the combination of Ibrutinib + GA101 + GDC-0199 Step C : 15 untreated patients receive the combination of Ibrutinib + GA101 + GDC-0199
Study: NCT00860509

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Phytosterol and High Phytosterol Diets
Description: Diets with 600 or 100 mg of daily phytosterols for 4 weeks were given to each subject, in random order

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Low Phytosterol and High Phytosterol Diets
Description: Diets with 600 or 100 mg of daily phytosterols for 4 weeks were given to each subject, in random order
Study: NCT02002429

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Saline injection
Description: Injection into the affected facet joint(s) with 0.5 ml of normal saline. All subjects in the group will receive radiofrequency denervation.
Study: NCT02369380

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid
Description: Injections of Hyaluronic acid under the metatarsal heads
Study: NCT01618357

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Patients will receive radiation therapy at a dose of 2.35 Gy per fraction to the breast and regional nodal region for 16 fractions to a total dose of 37.5 Gy. Treatments will be given Monday through Friday. Radiation therapy will start on day 1 of Veliparib.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumpectomy/Mastectomy
Description: Resection of breast cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Pills to be taken twice a day during radiation and for one week after completion of radiation for a total of 29 days.
Study: NCT04365699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-001
Description: Investigational novel Aldose Reductase Inhibitor (ARI) Product: AT-001 500mg capsule for oral administration Dosage: 1,500mg (3X500mg capsules) twice daily Mode of Administration: Oral Up to 14 days per discretion of the investigators and treatment team
Study: NCT02995785

Intervention type: OTHER
Group type: OTHER
Intervention: simulation-based training
Description: simulation-based training:The first aid skill simulation training with discussion and debriefing(75-min) and TMS online lecture(15-min).

Intervention type: OTHER
Group type: OTHER
Intervention: traditional training
Description: traditional training:Give TMS online lecture(15-min).

Intervention type: OTHER
Group type: OTHER
Intervention: traditional training
Description: traditional training:Give TMS online lecture(15-min).
Study: NCT02752932

Intervention type: OTHER
Group type: OTHER
Intervention: Drug testing on PDX per Investigator's choice (upto 4)
Description: Drug of Investigator's choice (upto 4 Ontario funded Chemotherapeutics) will be tested on PDX (Patient Derived Xenografts)

Intervention type: OTHER
Group type: OTHER
Intervention: Drug testing on PDX per Investigator's choice (upto 4)
Description: Drug of Investigator's choice (upto 4 Ontario funded Chemotherapeutics) will be tested on PDX (Patient Derived Xenografts)
Study: NCT01346267

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Real Acupressure Band
Description: Acupressure wristband

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Placebo Acupressure Band
Description: Sham wristband
Study: NCT03671291

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: self-administrated questionnaire
Description: Persons who the biological parameters or past screening show that they were recently infected with HIV cf. eligibility criteria, will, after obtaining his consent, answer a series of questions through a self-administrated questionnaire that will take approximately 40 minutes.
Study: NCT02812667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab + Plinabulin
Study: NCT01346384

Intervention type: DEVICE
Intervention: laryngeal tube (VBM Medizintechnik)
Description: laryngeal tube number 4
Study: NCT02696096

Intervention type: OTHER
Group type: OTHER
Intervention: FMRI
Description: all participants will complete 2 FMRIs

Intervention type: DRUG
Group type: OTHER
Intervention: Suboxone
Description: all participants will be prescribed Suboxone for 4 months during their study participation
Study: NCT03933241

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: nasal irrigation
Description: nasal irrigation after Transnasal transsphenoidal surgery for pituitary tumor
Study: NCT00134056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atrasentan hydrochloride
Description: Given orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Description: Docetaxel given IV and prednisone given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Docetaxel given IV and prednisone given orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Description: Docetaxel given IV and prednisone given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Docetaxel given IV and prednisone given orally

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Given orally
Study: NCT02951702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin Oral
Description: This arm will receive oral vancomycin 125 mg daily if high risk and determined to be appropriate by an ID physician
Study: NCT01769729

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PEPP

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Care management

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care management
Study: NCT01426217

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Passive Bundle PSI (Problem Solving Innovations) Medical HubScrub, PSI Medical DocIt
Description: Implementation of passive bundle which includes HubScrub and DocIt device into the operating room environment.
Study: NCT04647409

Intervention type: OTHER
Group type: OTHER
Intervention: screening
Description: The determination of the prevalence of NAFLD in a general population in Flanders, Belgium
Study: NCT02555397

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad5-yCD/mutTKSR39rep-hIL12
Description: Single intraprostatic injection of Ad5-yCD/mutTKSR39rep-hIL12 on day 1